the evolving treatment landscape of mhspc and mcrpc
Published 2 years ago • 251 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
2:34
first-line treatments for patients with mhspc and mcrpc
-
1:57
the evolving treatment landscape of prostate cancer
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
8:21
ep. 10: how has the mcrpc treatment landscape changed?
-
3:25
life expectancy with prostate cancer diagnosis
-
36:46
reversing metastatic bone cancer from prostate
-
16:39
metastatic castration resistant prostate cancer (mcrpc) – inroads in improved outcomes
-
4:21
evolving strategies in mhspc
-
44:49
'treatment landscape for metastatic hormone-sensitive prostate cancer' - dr laeeq malik grand rounds
-
3:15
how has covid-19 changed the treatment landscape of prostate cancer?
-
15:57
mhspc: chemo-hormonal therapy and treatment intensification
-
34:25
treatment options for the management of metastatic hormone-sensitive prostate cancer (mhspc)
-
20:07
management of mhspc
-
2:39
prospects and progress of treatments for mcrpc
-
2:26
caspar: the addition of rucaparib to enzalutamide for the treatment of mcrpc
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
1:39
challenges in the field of parpi treatment for mcrpc
-
1:04:24
urowebinar: new treatment options in mcrpc
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
8:53
prognostic biomarkers to guide treatment of mcrpc